Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up.

Aim Of The Study: To assess the long-term hepatitis C (HCV) treatment outcome in former injecting drug users (IDUs).

Materials And Methods: A long-term follow-up of 27 former IDUs who had been successfully treated for chronic hepatitis C was performed. These patients represented all IDUs who had obtained a sustained virological response in a Norwegian HCV treatment trial.

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.

Background: Preliminary results from combination therapy with interferon-alpha and ribavirin (IFN/Rib) in patients with chronic hepatitis C have been promising, with up to 50% sustained hepatitis C virus (HCV) RNA response. The aim of this study was to investigate whether a sustained HCV RNA response could be obtained with combination therapy in patients who were non-responders or relapsers after IFN treatment.

Methods: In a multicenter study we randomized 53 HCV RNA-positive patients into 2 treatment groups.

Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.

Patients with chronic hepatitis C respond differently when treated with interferon. We randomized 116 patients with chronic hepatitis C in order to compare two dosage regimens of recombinant interferon alpha 2a:3 MIU x 3 per week for 6 months (arm A) or 6 MIU x 3 per week for 3 months and then 3 MIU x 3 per week for 3 months (arm B). There were no significant differences concerning outcome between the two dose regimens: sustained clearance of HCV viremia 6 months after the end of treatment was obtained in 12/59 (20%) in group A compared with 18/57 (32%) in group B (p = 0.

Comparison of the sensitivity of four rapid assays for the detection of antibodies to HIV-1/HIV-2 during seroconversion.

Objectives: To compare the sensitivity of four rapid assays for the detection of antibodies against HIV-1 during early seroconversion.

Methods: Four rapid assays for the detection of antibodies to HIV-1/HIV-2 (SUDS HIV 1 + 2, TestPack HIV-1/HIV-2, HIV-SPOT and CAPILLUS HIV-1/HIV-2) were evaluated on 38 sera derived from 14 HIV-1 seroconverters, formerly tested with Abbott second- and third-generation HIV-1/HIV-2 enzyme immunoassay (EIA) and Diagnostic Biotechnology HIV blot 2.2.